<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00939692</url>
  </required_header>
  <id_info>
    <org_study_id>06TOR01</org_study_id>
    <nct_id>NCT00939692</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Torrent Pharmaceutical Ltd.'s Topiramate Tablets Under Fasted Conditions</brief_title>
  <official_title>Study to Evaluate the Bioequivalence of a Test Tablet Formulation of Topiramate (2 x 25 mg), Compared to an Equivalent Dose of a Commercially Available Reference Drug Product (Topamax®, Ortho-McNeil Neurologics, Inc.)in Fasted, Healthy, Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Torrent Pharmaceuticals Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Torrent Pharmaceuticals Limited</source>
  <brief_summary>
    <textblock>
      -  Objective:

             -  Compare the bioequivalence of a test topiramate formulation (Torrent
                Pharmaceuticals Limited) to an equivalent oral dose of the commercially available
                topiramate (Topamax®, Ortho-McNeil Neurologics, Inc.) in a test population of 26
                adult subjects under fasted conditions.

        -  Clinical Design:

             -  Studies were Randomized, Two-Way Crossover, Single-Dose,Open-Label in healthy human
                adult subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">April 2007</completion_date>
  <primary_completion_date type="Actual">March 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Plasma Concentration (Cmax)</measure>
    <time_frame>serial pharmacokinetic plasma concentrations were drawn prior to dose administration (0 hour) and at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48 and 72 hours after drug administration.</time_frame>
    <description>The maximum or peak concentration that the drug reaches in the plasma</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Concentration Versus Time Curve From Time 0 to Time t [AUC(0-t)]</measure>
    <time_frame>serial pharmacokinetic plasma concentrations were drawn prior to dose administration (0 hour) and at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48 and 72 hours after drug administration.</time_frame>
    <description>The area under the plasma concentration versus time curve, from time 0 to the time of the last measurable concentration (t)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Area Under the Plasma Concentration Versus Time Curve From Time 0 to Infinity AUC(0-∞)</measure>
    <time_frame>serial pharmacokinetic plasma concentrations were drawn prior to dose administration (0 hour) and at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48 and 72 hours after drug administration.</time_frame>
    <description>The area under the plasma concentration versus time curve from time 0 to infinity. AUC(0-∞) was calculated as the sum of AUC(0-t) plus the ratio of the last measurable plasma concentration to the elimination rate constant.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Torrent Topiramate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>tablet containing 25 mg of topiramate (Torrent Pharmaceuticals)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Topamax</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>tablet containing 25 mg of topiramate (Topamax®, Ortho-McNeil Neurologics, Inc.)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topiramate</intervention_name>
    <description>Topiramate (brand name Topamax) is an anticonvulsant (antiepilepsy) drug. IUPAC name 2,3:4,5-Bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate</description>
    <arm_group_label>Torrent Topiramate</arm_group_label>
    <arm_group_label>Topamax</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Sex: Male or Female; similar proportions of each preferred.

          -  Age: At least 18 - 55 years (inclusive).

          -  Weight: BMI (Body Mass Index) 19 kg/m2 - 30 kg/m2 (inclusive).

          -  Qualifying subjects must be in good health and physical condition as determined by
             medical history, complete physical examination, and laboratory tests, all obtained
             within four (4) weeks prior to study start. The subject may not have a history of
             significant past illness expected to affect the investigation. The normal status of
             subjects will be confirmed by the following procedures:

               -  Laboratory Tests: Serum pregnancy test (female subjects only), hemoglobin,
                  hematocrit, RBC, WBC, platelet count, differential count, serum electrolytes (Na,
                  K, Cl), fasting blood glucose, BUN, bilirubin, creatinine, AST, ALT, LD, alkaline
                  phosphatase, urinalysis, drugs of abuse, HIV, Hepatitis B, and Hepatitis C will
                  be done for screening purposes.

               -  Laboratory values which are greater than 20% of the normal range will not qualify
                  unless specifically accepted by a physician who is an investigator or
                  sub-investigator for the clinical trial. Results of a serum pregnancy test
                  (female subjects only), HIV, Hepatitis B, Hepatitis C, and drugs of abuse must be
                  negative or non-reactive for the subject to qualify for the study.

               -  Electrocardiogram: A 12-lead electrocardiogram (ECG) will be obtained for all
                  subjects. The original tracings, plus interpretation, will be included in the
                  case report form packet.

          -  Subjects must read and sign the Consent Form.

        Exclusion Criteria:

          -  Subjects not complying with the above inclusion criteria must be excluded from the
             study.

          -  In addition, any one (1) of the conditions listed below will exclude a subject from
             the study:

               -  History of treatment for alcoholism, substance abuse, or drug abuse within the
                  past 24 months.

               -  History of malignancy, stroke, diabetes, cardiac, renal or liver disease, or
                  other serious illness.

               -  History of GERD (gastroesophageal reflux disease), malabsorption syndrome, colon
                  cancer, or chronic colitis, including Crohn's disease.

               -  History of treatment for asthma within the past five (5) years.

               -  History of predisposition to renal calculi.

               -  History of surgery within the past eight (8) weeks.

               -  History of application of tattoo(s) within the past 30 days.

               -  History of body piercing(s) within the past 30 days.

               -  Females who are pregnant or lactating.

               -  History of hypersensitivity to topiramate or any anticonvulsant medication.

          -  Conditions upon screening which might contraindicate or require that caution be used
             in the administration of topiramate, including:

               -  Sitting systolic blood pressure below 90 mm Hg, or diastolic pressure below 50 mm
                  Hg.

               -  Heart rate less than 50 beats per minute after a 5-minute rest in a seated
                  position.

          -  Inability to read and/or sign the consent form.

          -  Treatment with any other investigational drug during the 30 days prior to the initial
             dosing for this study.

          -  Subjects who have donated blood within 30 days prior to the initial dosing for this
             study.

          -  Subjects who smoke more than 10 cigarettes per day.

          -  Subjects who do not tolerate venipuncture.

          -  Subjects who have difficulty fasting or consuming standardized meals.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Gateway Medical Research, Inc.</name>
      <address>
        <city>St, Charles</city>
        <state>Missouri</state>
        <zip>63301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 13, 2009</study_first_submitted>
  <study_first_submitted_qc>July 14, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 15, 2009</study_first_posted>
  <results_first_submitted>July 22, 2009</results_first_submitted>
  <results_first_submitted_qc>July 12, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 16, 2013</results_first_posted>
  <last_update_submitted>July 12, 2013</last_update_submitted>
  <last_update_submitted_qc>July 12, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 16, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Topiramate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Torrent's Topiramate First, Then Topamax</title>
          <description>For period one - on the morning of Day 1 subjects received two tablets of the test formulation, Torrent's Topiramate 25 mg.
Followed by a 21 day washout period.
For period two - on the morning of Day 1 subjects received two tablets of the reference formulation, Topamax 25 mg.</description>
        </group>
        <group group_id="P2">
          <title>Topamax First, Then Torrent's Topiramate</title>
          <description>For period one - on the morning of Day 1 subjects received two tablets of the reference formulation, Topamax 25 mg.
Followed by a 21 day washout period.
For period two - on the morning of Day 1 subjects received two tablets of the test formulation, Torrent's Topiramate 25 mg.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1 - First Intervention - 5 Days</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 2 - Second Intervent - 5 Days</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Torrent's Topiramate</title>
          <description>tablet containing 25 mg of topiramate (Torrent Pharmaceuticals Limited)</description>
        </group>
        <group group_id="B2">
          <title>Topamax</title>
          <description>tablet containing 25 mg of topiramate (Topamax®, Ortho-McNeil Neurologics, Inc.)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
            <count group_id="B2" value="13"/>
            <count group_id="B3" value="26"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.3" spread="10.9"/>
                    <measurement group_id="B2" value="30.3" spread="10.9"/>
                    <measurement group_id="B3" value="30.3" spread="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximum Plasma Concentration (Cmax)</title>
        <description>The maximum or peak concentration that the drug reaches in the plasma</description>
        <time_frame>serial pharmacokinetic plasma concentrations were drawn prior to dose administration (0 hour) and at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48 and 72 hours after drug administration.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Torrent's Topiramate</title>
            <description>tablet containing 25 mg of topiramate</description>
          </group>
          <group group_id="O2">
            <title>Topamax</title>
            <description>tablet containing 25 mg of topiramate (Topamax®, Ortho-McNeil Neurologics, Inc.)</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Plasma Concentration (Cmax)</title>
          <description>The maximum or peak concentration that the drug reaches in the plasma</description>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="265.96" spread="105.09"/>
                    <measurement group_id="O2" value="260.04" spread="85.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Concentration Versus Time Curve From Time 0 to Time t [AUC(0-t)]</title>
        <description>The area under the plasma concentration versus time curve, from time 0 to the time of the last measurable concentration (t)</description>
        <time_frame>serial pharmacokinetic plasma concentrations were drawn prior to dose administration (0 hour) and at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48 and 72 hours after drug administration.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Torrent's Topiramate</title>
            <description>tablet containing 25 mg of topiramate</description>
          </group>
          <group group_id="O2">
            <title>Topamax</title>
            <description>tablet containing 25 mg of topiramate (Topamax®, Ortho-McNeil Neurologics, Inc.)</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration Versus Time Curve From Time 0 to Time t [AUC(0-t)]</title>
          <description>The area under the plasma concentration versus time curve, from time 0 to the time of the last measurable concentration (t)</description>
          <units>mcg*hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.51" spread="0.94"/>
                    <measurement group_id="O2" value="1.25" spread="0.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Area Under the Plasma Concentration Versus Time Curve From Time 0 to Infinity AUC(0-∞)</title>
        <description>The area under the plasma concentration versus time curve from time 0 to infinity. AUC(0-∞) was calculated as the sum of AUC(0-t) plus the ratio of the last measurable plasma concentration to the elimination rate constant.</description>
        <time_frame>serial pharmacokinetic plasma concentrations were drawn prior to dose administration (0 hour) and at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48 and 72 hours after drug administration.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Torrent's Topiramate</title>
            <description>tablet containing 25 mg of topiramate</description>
          </group>
          <group group_id="O2">
            <title>Topamax</title>
            <description>tablet containing 25 mg of topiramate (Topamax®, Ortho-McNeil Neurologics, Inc.)</description>
          </group>
        </group_list>
        <measure>
          <title>The Area Under the Plasma Concentration Versus Time Curve From Time 0 to Infinity AUC(0-∞)</title>
          <description>The area under the plasma concentration versus time curve from time 0 to infinity. AUC(0-∞) was calculated as the sum of AUC(0-t) plus the ratio of the last measurable plasma concentration to the elimination rate constant.</description>
          <units>ng·h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17796.46" spread="3500.70"/>
                    <measurement group_id="O2" value="17770.47" spread="3944.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Torrent's Topiramate</title>
          <description>tablet containing 25 mg of topiramate (Torrent Pharmaceuticals Limited)</description>
        </group>
        <group group_id="E2">
          <title>Topamax</title>
          <description>tablet containing 25 mg of topiramate (Topamax®, Ortho-McNeil Neurologics, Inc.)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Walter A Parham</name_or_title>
      <organization>Gateway Medical Research, Inc.</organization>
      <phone>(314) 663-4550</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

